TNF-alpha Modulates the Migratory Response of Mesenchymal Stem Cells to TRAIL

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2010 Jan 12

PMID 20063037

Citations 11

Authors

Federica Corallini

Paola Secchiero

Antonio Paolo Beltrami

Daniela Cesselli

Elisa Puppato

Roberto Ferrari

Carlo Alberto Beltrami

Giorgio Zauli

Affiliations

Soon will be listed here.

Abstract

The number of circulating mesenchymal stem cells (MSC), analyzed after acute myocardial infarction (AMI), was lower in AMI patients who developed heart failure (HF) in the follow-up. Conversely, the circulating levels of tumor necrosis factor (TNF)-alpha, and osteoprotegerin (OPG) were higher in AMI patients who developed HF with respect to the patients who did not develop HF. In vitro exposure to TNF-alpha enhanced the migration of MSC in response to TNF-related apoptosis-inducing ligand (TRAIL) and significantly increased the release of OPG by endothelial cells. On the contrary, OPG dose-dependently neutralized the in vitro pro-migratory activity of TRAIL. Thus, TNF-alpha exhibits opposite effects on MSC migration driven by TRAIL: it is capable of potentiating MSC migration as well as of inhibiting MSC migration as an indirect consequence of OPG induction, which might result in a suboptimal recruitment of circulating MSC after AMI in those patients who develop HF in the follow-up.

Citing Articles

Osteoprotegerin Is Essential for the Development of Endothelial Dysfunction Induced by Angiotensin II in Mice.

Dutka M, Garczorz W, Kosowska A, Buczek E, Godek P, Wojakowski W Int J Mol Sci. 2024; 25(12).

PMID: 38928140 PMC: 11203749. DOI: 10.3390/ijms25126434.

Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases.

Dutka M, Bobinski R, Wojakowski W, Francuz T, Pajak C, Zimmer K Heart Fail Rev. 2021; 27(4):1395-1411.

PMID: 34313900 PMC: 9197867. DOI: 10.1007/s10741-021-10153-2.

TRAIL and Cardiovascular Disease-A Risk Factor or Risk Marker: A Systematic Review.

Kakareko K, Rydzewska-Rosolowska A, Zbroch E, Hryszko T J Clin Med. 2021; 10(6).

PMID: 33803523 PMC: 8002847. DOI: 10.3390/jcm10061252.

The relevance of microRNA in post-infarction left ventricular remodelling and heart failure.

Dutka M, Bobinski R, Korbecki J Heart Fail Rev. 2019; 24(4):575-586.

PMID: 30710255 PMC: 6560007. DOI: 10.1007/s10741-019-09770-9.

Potential clinical applications of adult human mesenchymal stem cell (Prochymal®) therapy.

Patel A, Genovese J Stem Cells Cloning. 2013; 4:61-72.

PMID: 24198531 PMC: 3781758. DOI: 10.2147/SCCAA.S11991.

References

Schoppet M, Sattler A, Schaefer J, Herzum M, Maisch B, Hofbauer L . Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003; 88(3):1024-8. DOI: 10.1210/jc.2002-020775. View

Niessner A, Hohensinner P, Rychli K, Neuhold S, Zorn G, Richter B . Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J. 2009; 30(7):789-96. DOI: 10.1093/eurheartj/ehp004. View

Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B . An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol. 2006; 169(6):2236-44. PMC: 1762477. DOI: 10.2353/ajpath.2006.060398. View

Satoh D, Inami N, Shimazu T, Kajiura T, Yamada K, Iwasaka T . Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease. J Thromb Thrombolysis. 2009; 29(4):471-6. DOI: 10.1007/s11239-009-0364-9. View

Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A . Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004; 109(18):2175-80. DOI: 10.1161/01.CIR.0000127957.43874.BB. View

Avignon A, Sultan A, Piot C, Elaerts S, Cristol J, Dupuy A . Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care. 2005; 28(9):2176-80. DOI: 10.2337/diacare.28.9.2176. View

Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G . Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res. 2003; 92(7):732-40. DOI: 10.1161/01.RES.0000067928.83455.9C. View

Feldman A, Combes A, Wagner D, Kadakomi T, Kubota T, Li Y . The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000; 35(3):537-44. DOI: 10.1016/s0735-1097(99)00600-2. View

Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T . Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004; 44(10):1970-6. DOI: 10.1016/j.jacc.2004.06.076. View

10.

Zauli G, Secchiero P . The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev. 2006; 17(4):245-57. DOI: 10.1016/j.cytogfr.2006.04.002. View

11.

Ozaki Y, Nishimura M, Sekiya K, Suehiro F, Kanawa M, Nikawa H . Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells. Stem Cells Dev. 2007; 16(1):119-29. DOI: 10.1089/scd.2006.0032. View

12.

Secchiero P, Corallini F, di Iasio M, Gonelli A, Barbarotto E, Zauli G . TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood. 2005; 105(9):3413-9. DOI: 10.1182/blood-2004-10-4111. View

13.

Sun J, Li S, Liu S, Wu J, Weisel R, Zhuo Y . Improvement in cardiac function after bone marrow cell thearpy is associated with an increase in myocardial inflammation. Am J Physiol Heart Circ Physiol. 2008; 296(1):H43-50. DOI: 10.1152/ajpheart.00613.2008. View

14.

Grundmann F, Scheid C, Braun D, Zobel C, Reuter H, Schwinger R . Differential increase of CD34, KDR/CD34, CD133/CD34 and CD117/CD34 positive cells in peripheral blood of patients with acute myocardial infarction. Clin Res Cardiol. 2007; 96(9):621-7. DOI: 10.1007/s00392-007-0543-7. View

15.

Kim Y, Park H, Hong M, Kang P, Morgan J, Jeong M . TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. Front Biosci (Landmark Ed). 2009; 14(8):2845-56. DOI: 10.2741/3417. View

16.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

17.

Secchiero P, Melloni E, Corallini F, Beltrami A, Alviano F, Milani D . Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells. 2008; 26(11):2955-63. DOI: 10.1634/stemcells.2008-0512. View

18.

Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R . Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 2004; 105(1):199-206. DOI: 10.1182/blood-2004-05-1831. View

19.

Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V . TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci. 2004; 61(15):1965-74. PMC: 11138819. DOI: 10.1007/s00018-004-4197-6. View

20.

Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland S . Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005; 111(19):2461-8. DOI: 10.1161/01.CIR.0000165119.62099.14. View